Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M177,649Revenue (TTM) $M39,929Net Margin (%)10.9Altman Z-Score3.3
Enterprise Value $M191,125EPS (TTM) $1.6Operating Margin %16.2Piotroski F-Score7
P/E(ttm)41.7Beneish M-Score-2.7Pre-tax Margin (%)12.6Higher ROA y-yY
Price/Book4.510-y EBITDA Growth Rate %3.4Quick Ratio1.3Cash flow > EarningsY
Price/Sales4.55-y EBITDA Growth Rate %-3.4Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow26.5y-y EBITDA Growth Rate %-13.0ROA % (ttm)4.5Higher Current Ratio y-yN
Dividend Yield %2.9PEG--ROE % (ttm)10.3Less Shares Outstanding y-yY
Payout Ratio %118Shares Outstanding M2,735ROIC % (ttm)9.5Gross Margin Increase y-yY

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

MRK is held by these investors:


News about MRK:

Articles On GuruFocus.com
Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna May 23 2017 
Osteoporosis Drug Meets Primary and Secondary Endpoints May 23 2017 
Howard Marks on the Truth About Investing May 19 2017 
US Market Indexes Higher on Thursday May 18 2017 
Tweedy Browne Hooks Up Baidu in 1st Quarter May 17 2017 
Nasdaq Closes at 6121, Stocks Mostly Lower May 12 2017 
Kahn Brothers Sells Hologic, Pfizer, Citigroup May 11 2017 
Merck Collaborates With OncoSec Medical to Unlock Untapped Market for Keytruda May 10 2017 
US Market Indexes Mostly Lower May 09 2017 
Stocks Lower With Disappointing Earnings From Apple May 03 2017 

More From Other Websites
Optum and Merck Collaborate to Advance Value-Based Contracting of Pharmaceuticals May 25 2017
Major Pharma Short Interest Surges May 25 2017
Radius Health Osteoporosis Drug Positive in Phase III Study May 25 2017
Performance of Merck’s Animal Health Segment in 1Q17 May 25 2017
Blog Coverage Merck's KEYTRUDA Becomes First Cancer Drug to be Approved by FDA Based on a Common... May 25 2017
Merck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody... May 25 2017
Merck’s Immunology and Cardiovascular Franchise in 1Q17 May 25 2017
Performance of Merck’s Diabetes Portfolio in 1Q17 May 24 2017
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk May 24 2017
Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers May 24 2017
Gardasil and Merck’s Vaccines Business in 1Q17 May 24 2017
1Q17 Performance of Keytruda, Merck’s Blockbuster Drug May 24 2017
FDA Approves Merck’s Keytruda to Treat Cancers With Genetic Defects May 23 2017
FDA clears Merck's Keytruda based on cancer genetics, not location May 23 2017
Merck Presents Phase II Data on Chronic Cough Candidate May 23 2017
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable... May 23 2017
The FDA just took an entirely new approach to approving a cancer drug May 23 2017
Merck Announces Third-Quarter 2017 Dividend May 23 2017
Merck & Co.’s Segmental Performance in 1Q17 May 23 2017
Why Merck & Co. Continued to Grow in 1Q17 May 23 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)